10363 results for 'filter m face'

Why do powerful cancer immunotherapies work wonders for some patients but fail for others? The answer may lie not just in the cancer cells themselves, but in the energy levels of our own immune warrio

Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines

蛋白质印迹样本方案（Western Blot，中文） | Assay Genie

HIV Virus: Replication Cycle and Pathogenesis in absence of HAART The human immunodeficiency virus (HIV) is a formidable pathogen that has posed a significant global

You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a

The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread In the intricate battlefield of the human body, the immune system’s foot soldiers, neutrophils, have long been re

Un compte rendu ELISA exploitable réunit l’objectif de l’essai, la référence et le lot du kit, la méthode suivie, les densités optiques brutes, le modèle d’ajustement retenu (4PL ou 5PL) et les fa

By Sonika Singh PhD candidate, University of Nottingham A Devastating Disease Multiple Sclerosis (MS) is a chronic and inflammatory disease based on

By Charlotte O’Donnell PhD Cancer Carcinogenesis is a multi-step process that develops through epigenetic changes and muta

Introduction to FoxP3 and Regulatory T Cells in CancerFoxP3 (forkhead box P3) is a transcription factor critical for the development and function of regulatory T cells (Tregs), a speciali

Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tu

Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.

Dr. Melissa Conroy, TTMI I am an immunologist and senior research fellow in the Cancer Immunology and Immunotherapy Group, Department of Surgery at Trinity

Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f

Chronic myelogenous leukaemia (CML) is a myeloproliferative haematopoietic malignancy, characterised by a karyotypic abnormality present in more than 95% of cases known as the Philadelph

Preeclampsia is a serious condition that can develop during pregnancy. It is marked by high blood pressure and the presence of protein in the urine and can cause serious problems for b

What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a

Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do

Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does

Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym